Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ABCL

ABCL - AbCellera Biologics Inc Stock Price, Fair Value and News

$3.83-0.33 (-7.93%)
Market Closed

38/100

ABCL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

38/100

ABCL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ABCL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABCL Price Action

Last 7 days

4.3%

Last 30 days

27.2%

Last 90 days

6.7%

Trailing 12 Months

60.6%

ABCL RSI Chart

ABCL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABCL Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-8.61

Price/Sales (Trailing)

16.79

EV/EBITDA

-7.53

Price/Free Cashflow

-7.25

ABCL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ABCL Fundamentals

ABCL Revenue

Revenue (TTM)

75.1M

Rev. Growth (Yr)

788.28%

Rev. Growth (Qtr)

400.88%

ABCL Earnings

Earnings (TTM)

-146.4M

Earnings Growth (Yr)

73.85%

Earnings Growth (Qtr)

84.34%

ABCL Profitability

EBT Margin

-236.39%

Return on Equity

-15.14%

Return on Assets

-10.79%

Free Cashflow Yield

-13.8%

ABCL Investor Care

Shares Dilution (1Y)

1.74%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202523.1M32.9M35.3M75.1M
202435.8M33.1M33.0M28.8M
2023373.6M261.7M149.9M38.0M
2022489.0M507.3M603.2M485.4M
2021431.2M447.7M443.8M375.2M
202067.0M122.4M177.8M233.2M
201900011.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About AbCellera Biologics Inc

ABCL
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
 CEO
 WEBSITEabcellera.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES590

AbCellera Biologics Inc Frequently Asked Questions

ABCL is the stock ticker symbol of AbCellera Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Apr 28 2026, market cap of AbCellera Biologics Inc is 1.26 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Apr 28 2026, ABCL's PE ratio (Price to Earnings) is -8.61 and Price to Sales (PS) ratio is 16.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABCL PE ratio will change depending on the future growth rate expectations of investors.